经阴道彩色多普勒超声检查联合血清CA125检测监测卵巢癌术后复发  

Transvaginal Color Doppler Ultrasonography and CA125 Detection in Surveillance of Ovarian Malignant Tumors after Operation

作　　者：曾辉[1] 裴小青[1] 郑丹苗[1] 赵雁梨[1] 陈孝岳[1] 

机构地区：[1]华南肿瘤学国家重点实验室

出　　处：《癌症》2006年第10期1296-1299,共4页Chinese Journal of Cancer

基　　金：中山大学肿瘤防治中心单病种科研基金(No.590)~~

摘　　要：背景与目的:经阴道彩色多普勒血流显像(transvaginalultrasonographycolordopplerflowimaging,TV-CDFI)已广泛应用于超声诊断,但TV-CDFI与血清CA125联合检查,监测卵巢癌术后复发的文献报道较少。本研究探讨TV-CDFI与血清CA125联合监测卵巢癌术后复发的诊断价值。方法:对62例卵巢癌切除术后患者进行TV-CDFI检查,同时检测血清CA125值,将检查结果与病理组织学诊断对照,分别计算各单项检测与两者结合后诊断的敏感性、特异性和准确性。结果:单独应用TV-CDFI或血清CA125检测,对卵巢癌术后复发的诊断敏感性分别为84.6%、65.4%,特异性分别为88.9%、66.7%,准确率分别为87.1%、66.1%;两项检查相结合,诊断的敏感性、特异性分别为92.3%、88.9%,准确率提高至90.3%(P<0.05)。结论:单独应用TV-CDFI可以对大多数卵巢癌术后复发性肿瘤作出诊断;若联合血清CA125检测,则能进一步提高其诊断的准确率,是卵巢癌术后监测和随访的有效方法。BACKGROUND ＆ OBJECTIVE, Although transvaginal ultrasonography color Doppler flow imaging （TV-CDFI） has been widely applied in ultrasonography diagnosis, studies on TV-CDFI combined with a serum tumor marker CA125 detection in the surveillance of ovarian malignant tumors after operation are few. This study was to evaluate TV-CDFI combined with CA125 detection in the surveillance of ovarian malignant tumors after operation. METHODS. Sixty-two cases of ovarian malignant tumors after operation were examined by TV-CDFI. The level of CA125 was measured, and the results were evaluated compared with pathologic findings, The diagnostic sensitivity, specificity, and accuracy were calculated. RESULTS. The diagnostic sensitivity of TV-CDFI or CA125 alone was 84.6% and 65.4%; the specificity was 88.9% and 66.7%; the accuracy was 87.1% and 66.1%. While the diagnostic sensitivity of TV-CDFI combined with CA125 was 92.3%, the specificity was 88.9%, and the accuracy rate rose to 90.3% （P〈0.05）. CONCLUSION. The diagnostic accuracy for recurrent ovarian malignant tumors is improved by TV-CDFI combined with CA125, which is more helpful in the surveillance of recurrent ovary malignant tumors than TV-CDFI alone.

关 键 词：卵巢肿瘤/外科手术 复发 经阴道彩色多普勒超声 血清CA125 诊断 监测 

分 类 号：R737.31[医药卫生—肿瘤]